Expert meeting report: epidemiology and management of acquired hypothalamic obesity - Takeaways - MDSpire

Expert meeting report: epidemiology and management of acquired hypothalamic obesity

  • By

  • Hermann L. Müller

  • Ute K. Bartels

  • Christian Denzer

  • Ulrich Dischinger

  • Jörg Flitsch

  • Johannes Gojo

  • Annette Richter-Unruh

  • Katrin Scheinemann

  • Katharina Schilbach

  • Carsten Friedrich

  • April 15, 2026

  • 0 min

Share

  • 1

    Acquired hypothalamic obesity (aHO) results from hypothalamic damage and leads to significant, persistent weight gain.

  • 2

    aHO is associated with increased morbidity, mortality, and impaired quality of life due to metabolic syndrome and cardiovascular risks.

  • 3

    Pharmacological treatments like dextroamphetamine and GLP-1 receptor agonists show promise for managing weight and hyperphagia in aHO.

  • 4

    Preliminary results from the TRANSCEND trial indicate that setmelanotide significantly reduces BMI in individuals with aHO.

  • 5

    Long-term management of aHO requires a supportive environment and structured behavioral coaching to achieve durable weight control.

Original Source(s)

Expert meeting report: epidemiology and management of acquired hypothalamic obesity

  • by Hermann L. Müller, Ute K. Bartels, Christian Denzer, Ulrich Dischinger, Jörg Flitsch, Johannes Gojo, Annette Richter-Unruh, Katrin Scheinemann, Katharina Schilbach, Carsten Friedrich

  • April 15, 2026

Related Content

Metabolic and bariatric surgery in mild obesity: mid-term outcomes and safety in an Asian population

Association of CTI and its obesity-related derivatives with incident depression among middle-aged and older adults across CKM stages 0-4: a nationwide prospective cohort study and external clinical validation

Pasteurized Akkermansia muciniphila alleviates high-fat diet-induced bone loss via Nr4a1-dependent Treg differentiation